<DOC>
	<DOC>NCT02089308</DOC>
	<brief_summary>The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine patch to that of a reference formulation following repeated applications</brief_summary>
	<brief_title>Nicotine Patch - Bioequivalence Study</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy male subject aged 18 to 45 years (inclusive) Current Smoker of &gt;or = 5 and &lt; or = to 15 cigarettes/day Fagerstr√∂m score &lt; or =5 at selection Absence of any clinically significant abnormal findings at physical examination, vital sign, Electrocardiogram ECG, biological examinations in the investigator's opinion. Presence of any significant medical findings or significant history (in particular any cardiovascular disease, severe renal or hepatic insufficiency, current gastric or duodenal ulcer) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable to interfere with use or safety assessment of a transdermal patch</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Tobacco Use Disorder</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>